. 2021 Dec 24;14(1):57. doi: 10.3390/nu14010057

Table 4.

Microbiota (log cfu/g feces) in patients with prediabetes of the PLC and MO groups during the intervention.

		0 wk	6 wk	12 wk	p ^#	Rate of Change 0–12 wk (p ^Φ)
Blautia coccoides- Eubacterium rectale	PLC	11.56 ± 0.29	11.61 ± 0.45	11.75 ± 0.29	0.218	1.7 ± 3.3
	MO	11.63 ± 0.32	11.72 ± 0.39	11.70 ± 0.38	0.218	0.7 ± 3.6
						NS
Bacteroides fragilis group.	PLC	9.38 ± 0.80	9.39 ± 0.84	9.42 ± 0.67	0.482	0.6 ± 5.5
	MO	9.59 ± 0.49	9.61 ± 0.57	9.58 ± 0.58	0.482	−0.1 ± 4.5
						NS
Clostridium cluster IV	PLC	8.39 ± 0.36	8.38 ± 0.58	8.49 ± 0.36	0.613	1.2 ± 5.2
	MO	8.43 ± 0.33	8.47 ± 0.33	8.47 ± 0.39	0.613	0.5 ± 4.8
						NS
Bifidobacterium spp.	PLC	7.76 ± 0.40	7.85 ± 0.47	7.90 ± 0.39	0.697	1.9 ± 4.8
	MO	7.78 ± 0.39	7.85 ± 0.40	7.83 ± 0.41	0.697	0.9 ± 5.8
						NS
Enterobacteriaceae	PLC	6.59 ± 1.15	6.56 ± 0.96	6.64 ± 1.02	0.404	3.5 ± 22.5
	MO	6.18 ± 0.86	6.42 ± 1.07	6.57 ± 0.90	0.404	7.7 ± 17.5
						NS
Enterococcus spp.	PLC	4.74 ± 1.02	5.14 ± 1.09	5.04 ± 1.0	0.016	9.1 ± 23.1
	MO	4.89 ± 0.97	4.62 ± 0.80	4.87 ± 0.78	0.016	2.5 ± 21.9
						NS
Lactobacillus group	PLC	4.34 ± 1.15	4.49 ± 1.06	4.67 ± 0.99	0.091	11.8 ± 26.9
	MO	4.37 ± 0.80	4.05 ± 0.74	4.33 ± 0.70	0.091	1.0 ± 18.6
						NS
Faecalibacterium prausnitzii	PLC	9.33 ± 0.36	9.38 ± 0.39	9.46 ± 0.35	0.438	1.5 ± 4.4
	MO	9.42 ± 0.30	9.49 ± 0.35	9.46 ± 0.38	0.438	0.5 ± 4.0
						NS
Akkermansia muciniphila	PLC	7.34 ± 1.25	6.99 ± 1.58	7.18 ± 1.43	0.885	−1.3 ± 16.7
	MO	7.19 ± 1.26	6.69 ± 1.33	6.96 ± 1.56	0.885	−0.5 ± 27.0
						NS

Between-group differences were assessed with a GLM with within-subject factor “visit”, the fixed factor “treatment” and the interaction “treatment × visit”. The p ^#-value corresponds to the “treatment × visit” factor. p ^Φ, Comparison between treatment groups by independent sample T test. NS, not significant.